<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03636620</url>
  </required_header>
  <id_info>
    <org_study_id>LC-TACE+RFA/MV</org_study_id>
    <nct_id>NCT03636620</nct_id>
  </id_info>
  <brief_title>TACE Combined With RFA/MV Treatment in Hepatocellular Carcinoma Beyond Milan Criterial</brief_title>
  <acronym>TACE+RFA</acronym>
  <official_title>Clinical Trial of Transcatheter Arterial Chemoembolization Combined With Radiofrequency/Microwave Ablation in Hepatocellular Carcinoma Beyond Milan Criterial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was designed to evaluate the effectiveness of radiofrequency /microwave ablation
      in patients with hepatocellular carcinoma beyond Milan Criteria.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to included 120 patients with intermediate stage hepatocellular
      carcinoma beyond Milan criteria .These patients were randomizedly allocated to TACE treatment
      group or TACE+RFA/MV .The treatment effectiveness, local tumor control and survival outcome
      between the two groups were compared.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2013</start_date>
  <completion_date type="Actual">August 2018</completion_date>
  <primary_completion_date type="Actual">August 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>TACE vs.TACE+RFA</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>up to 46 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>objective response rate</measure>
    <time_frame>up to 46 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">110</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>TACE group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Transcatheter arterial chemoembolization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TACE+RFA/MV group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transcatheter arterial chemoembolization and radiofrequency /microwave ablation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcatheter arterial chemoembolization</intervention_name>
    <description>Transcatheter arterial chemoembolization</description>
    <arm_group_label>TACE group</arm_group_label>
    <arm_group_label>TACE+RFA/MV group</arm_group_label>
    <other_name>TACE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>radiofrequency ablation/microwave ablation</intervention_name>
    <description>radiofrequency ablation/microwave ablation</description>
    <arm_group_label>TACE+RFA/MV group</arm_group_label>
    <other_name>RFA/MW</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients diganosed with hepatocellualr carcinoma beyond Milan criteria

          -  the presence of a single HCC tumor ≤7 cm in diameter, or multi-nodular HCC tumors (n ≤
             5) small than 7 cm in diameter;

          -  Child-Pugh A or B

          -  ECOG score 0-1;

          -  prothrombin time ≤16 s;

          -  white cell count ≥3,000/mm3, platelet count ≥40 x 109/L;Hb≥8.5 g/d;
             ALT/AST≤5×ULN;TB≤3mg/dl;alb≥2.8 g/dl ;Scr ≤2mg/dl

        Exclusion Criteria:

          -  expected survival time &lt; 12 months before random assignment;

          -  received anticancer surgery or procedure within one month before assignment;

          -  concomitant use of any other anticancer therapy(except immunotherapy and herbal
             medicine ) ;

          -  existence of portal of hepatic vein invation or extrahepatic metastases;existence of
             active infection ;

          -  upper gastrointestinal hemorrhage within one month ; .other serious illness or medical
             condition.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>zheng-gang Ren, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>liver cancer institute ,Fudan University</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 8, 2018</study_first_submitted>
  <study_first_submitted_qc>August 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2018</study_first_posted>
  <last_update_submitted>August 15, 2018</last_update_submitted>
  <last_update_submitted_qc>August 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Zheng-Gang Ren</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>no plan to make individual paticipant data available to other researchers</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

